Geographic Atrophy

Latest News

Image Credit: ©desertsands -
First Patient receives dosing with AVD-104 in the Phase 2 SIGLEC trial for the treatment of Geographic Atrophy

June 2nd 2023

Aviceda Therapeutics doses its first patient with AVD-104 in its Phase 2 SIGLEC Trial. This intravitreal asset is being tried for treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Image Credit: ©ronstik -
Patent filed by Curative Biotechnology with international consideration

May 28th 2023

Image Credit: ©Clayton D/ -
Annexon announces topline results from ARCHER Phase 2 trial of ANX007 for geographic atrophy (GA)

May 26th 2023

Image Credit: ©catalin -
Adverum Biotechnologies presents gene therapy data and introduces an intravitreal gene therapy program for geographic atrophy

May 19th 2023

©mik_cz /
ARVO 2023: Lineage Cell Therapeutics presents results of RG6501 Phase 1/2a clinical trial for treatment of GA progression

April 29th 2023

Video Interviews

More News

© 2023 MJH Life Sciences

All rights reserved.